GLAND PHARMA
|
|
BOM : 543245     NSE : GLAND     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Good [Stock is Cheap] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward Pledged Shares : NA |
Dec 13,2024 |
Price(EOD): ₹ 1,748.20
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 28,810.34 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
GLAND PHARMA | -2.4% | -0.8% | -1.3% |
SUN PHARMACEUTICAL INDUSTRIES | 0.4% | 0.8% | 45.4% |
CIPLA | -1.5% | -5.1% | 20.3% |
DR REDDYS LABORATORIES | -0.7% | -1.3% | 13.8% |
ZYDUS LIFESCIENCES | -0.5% | 3% | 54.1% |
DIVIS LABORATORIES | -1.4% | 1.2% | 62% |
MANKIND PHARMA | 0% | 0.5% | 38.1% |
TORRENT PHARMACEUTICALS | 0.4% | 6.3% | 60.1% |
LUPIN | -1.5% | -0.6% | 72.3% |
FUNDAMENTAL ANALYSIS OF GLAND PHARMA
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF GLAND PHARMA
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
41.65
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 691.57 Cr
[Latest Qtr - Sep2024 - Consolidated Results ] 3.3
P/B Calculated based on Book Value of Rs 8,722.46 Cr
[Latest Year - Mar2024 - Consolidated Results ] 4.89
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 5,890.15 Cr
[Latest Qtr - Sep2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
-37% -63% -63% |
SHARE PRICE MOMENTUM OF GLAND PHARMA
GLAND PHARMA vs SENSEX
DEBT OF GLAND PHARMA
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0 0 0 - |
0.04 0 0 0.01 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF GLAND PHARMA
Pledged Promoter Shares |
NA | |
---|---|---|
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF GLAND PHARMA
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
0.29% 12.35% 17.66% 13.75% |
2.36% -8.34% -11.42% -15.74% |
QtrlyTrend |
2 | |
Latest Qtr: Sep2024 | ||
Quarterly Result Analysis → |
GLAND PHARMA related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE 200 | 0.3% | 3.1% | 23.2% |
S&P BSE 250 LARGEMIDCAP | 0.2% | 3.2% | 23.3% |
S&P BSE LARGE MIDCAP | 0.2% | 3.2% | 22.9% |
S&P BSE MID CAP | 0.2% | 4.5% | 35.4% |
S&P BSE 150 MIDCAP | 0.2% | 4.4% | 34.4% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY MIDCAP150 | 0.4% | 4.8% | 32.2% |
NIFTY LARGE MIDCAP 250 | 0.3% | 3.8% | 27% |
NIFTY 500 | 0.2% | 3.4% | 24.9% |
NIFTY500 MULTICAP 50:25:25 | 0.1% | 3.8% | 27.9% |
NIFTY MID SMALL400 | 0.1% | 4.8% | 33.4% |
You may also like the below Video Courses
FAQ about GLAND PHARMA
Is GLAND PHARMA good for long term investment?
As on Dec 13,2024, the Fundamentals of GLAND PHARMA look Strong and hence it may be good for long term investment! See Financial Performance of GLAND PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is GLAND PHARMA UnderValued or OverValued?
As on Dec 13,2024, GLAND PHARMA is Under Valued based on the estimates of intrinsic value and hence may be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of GLAND PHARMA ?
As on Dec 13,2024, the Intrinsic Value of GLAND PHARMA is Rs. 4,733.16 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 2,784.13
Fair Value [Median EV / Sales Model] : Rs. 4,733.16
Fair Value [Median Price / Sales Model] : Rs. 4,775.22
Estimated Median Fair Value of GLAND PHARMA : Rs. 4,733.16
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.